- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06350279
A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects
April 1, 2024 updated by: Haisco Pharmaceutical Group Co., Ltd.
A Single and Multiple Ascending Dose Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects
This is a Phase I, randomized, subject-blinded, placebo controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD),and food effect (FE) of HSK39297 following (1) a single ascending dose (part 1), (2) 10 days of multiple ascending dose (part 2), and (3) a single dose two-period crossover FE cohort.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
96
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Meixia Chen, PhD
- Phone Number: 028-67258779
- Email: chenmeixia@haisco.com
Study Contact Backup
- Name: Laichun Lu
- Phone Number: 010-58268486
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Tongren Hospital
-
Contact:
- Laichun Lu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Voluntarily sign the informed consent form, understand the trialprocedures, and be willing to comply with all trial procedures andrestrictions;
- 18 years to 45 years (inclusive), male and female;
- Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Bodymass index (BMI) : 18-26 kg/m2 (inclusive) ;
- Subjects are willing to voluntarily use effectivecontraceptives from screening to at least 3 months after the last dose administration.
Exclusion Criteria:
- Have a history of severe and uncontrolled diseases, such ascardiovascular, respiratory, liver, gastrointestinal, endocrine,hematologic, mental/nervous systems diseases within 3 months prior to screening;
- Have an infection that requires systematic treatment with antibiotics, antifungal, antiparasitic or antiviral drugs;
- Have a clear history of capsular bacteria infection within 6 months before screening, inncluding but not limited to Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae B, etc.;
- Have a history of TB infection or are currently infected with TB;
- Have a history of any malignant tumors;
- The abnormalities were clinically significant during the screening period, such as physical examination, vital signs, blood biochemistry, blood routine, coagulation, urine routine, blood pregnancy test, infectious diseases and X-ray;
- Subjects whose results of routine 12-lead electrocardiograms were inconsistent with normal heart conduction and function;
- Previous or current gastrointestinal, liver, kidney, or other disease known to interfere with drug absorption, distribution, metabolism, or excretion;
- Smoking more than 5 cigarettes per day within 3 months prior toscreening or smoking during the study;
- Average alcohol intake is more than 14 unit per week (1unit=10g alcohol , 1 unit=285 mL 4.9% alcohol beer, or 30 mL 40% alcohol spirit, or 100mL 12% alcohol wine) within the 3 months prior to screening;
- Have a history of drug abuse prior to screening, or positive urine drug screen at screening;
- Have a history of high consumption of grapefruit juice, methylxanthinerich food or beverage (such as coffee, tea, cola, chocolate, energydrinks) ,consumption of grapefruit juice, methylxanthine-rich food within 48 hours before the administration;
- Blood donation (or blood loss) ≥400 mL, or receiving blood products to improve anemia within 3 months prior to the screening;
- Subjects who have a allergic to any component of HSK30297 or allergic history to opiates;
- Any drug that inhibits or induces drug metabolism enzymes or P-gp inhibitor have been administered within 28 days prior to initial administration of the investigational drug;
- Subjects who use any live vaccine within 30 days prior to screening;
- Have participated in any clinical investigator within 3 months prior to screening;
- A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial;
- Not suitable for this study as judged by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Placebo
|
50-600mg
|
Experimental: HSK39297
Single or multiple oral doses of HSK39297
|
50-600mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number and severity of treatment emergent adverse events (TEAEs) .
Time Frame: 9 days after single dose and 16 days after the first dose of multiple doses
|
To assess the safety and tolerability of single or multiple oral dose of HSK39297 in healthy adult volunteers
|
9 days after single dose and 16 days after the first dose of multiple doses
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC
Time Frame: Pre-dose to 168 hours post-dose
|
Area under the plasma concentration versus time curve (AUC) on Day 1 and D10
|
Pre-dose to 168 hours post-dose
|
Cmax
Time Frame: Pre-dose to 168 hours post-dose
|
The maximun plasma concentration of HSK39297
|
Pre-dose to 168 hours post-dose
|
Tmax
Time Frame: Pre-dose to 168 hours post-dose
|
Time of maximum concentration of HSK39297
|
Pre-dose to 168 hours post-dose
|
t1/2
Time Frame: Pre-dose to 168 hours post-dose
|
half-life
|
Pre-dose to 168 hours post-dose
|
AP change
Time Frame: Pre-dose to 168 hours post-dose
|
change from baselin of the alternative pathway activity
|
Pre-dose to 168 hours post-dose
|
Bb
Time Frame: Pre-dose to 168 hours post-dose
|
change from baselin of the concentration of Bb
|
Pre-dose to 168 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 25, 2023
Primary Completion (Estimated)
May 31, 2024
Study Completion (Estimated)
July 31, 2024
Study Registration Dates
First Submitted
April 1, 2024
First Submitted That Met QC Criteria
April 1, 2024
First Posted (Actual)
April 5, 2024
Study Record Updates
Last Update Posted (Actual)
April 5, 2024
Last Update Submitted That Met QC Criteria
April 1, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HSK39297-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet